

Q3 FY19 Financial results

“Third quarter performance was strong. Our revenues highlight the breadth and diversity of the growth drivers in our portfolio, and we are seeing strength across all three segments. As anticipated, our performance has accelerated, and we expect this momentum to continue. We are successfully integrating Bard, as evidenced by our sustained top-line momentum and cadence of new product launches. We remain confident in our outlook for fiscal year 2019 and our ability to deliver value to customers and shareholders.”

—Vince Forlenza, Chairman and CEO



Q3 revenue performance

 **\$4.4B** | **+5.7%¹**

Adjusted Q3 EPS²

 **\$3.08** | **+14.8%**

Q3 revenue performance by segment¹



BD Medical

+6.0%



BD Interventional

+5.2%



BD Life Sciences

+5.4%

Fiscal 2019 guidance



Revenue¹

+5.0% to +6.0%



Adjusted EPS²

\$11.65 to \$11.75

1. Reflects growth on a currency neutral basis, adjusted to exclude divestitures and other items, as applicable.

2. Adjusted earnings per share growth rate is presented on a currency neutral basis. Adjusted diluted earnings per share results exclude, among other things, the impact of purchase accounting adjustments (including the non-cash amortization of acquisition-related intangible assets); integration, and restructuring and transaction costs.

These materials include non-GAAP financial measures. A reconciliation to the comparable GAAP measures can be found in our third quarter earnings release and the financial schedules attached thereto, furnished as an exhibit to the 8-K that BD filed today with the SEC.

This document contains forward-looking statements and it's possible that actual results could differ from our expectations. Factors that could cause such differences appear in our third quarter earnings release and in our recent SEC filings.

